The therapeutic potential of harmine and ayahuasca in depression : Evidence from exploratory animal and human studies Flávia de Lima Osório, Ligia Ribeiro Horta de Macedo, João Paulo Machado de Sousa, Joel Porfírio Pinto, João Quevedo, José Alexandre de Souza Crippa and Jaime Eduardo C. Hallak The Ethnopharmacology of Ayahuasca, chapitre 5, 2011, 75-85 Editor : Rafael Guimarães dos Santos ISBN: 978-81-7895-526-1 Abstract The high prevalence and the socio-functional impairment associated with depressive disorders, added to the limitations of currently available treatments, justify the search for novel pharmacological strategies for the management of depression. This chapter presents the major results of animal and human studies conducted [...]
Lire la suiteAyahuasca in Adolescence : A Neuropsychological Assessment Evelyn Doering-Silveira, Enrique Lopez, Charles S. Grob, Marlene Dobkin de Rios, Luisa K. Alonso, Cristiane Tacla,Itiro Shirakawa, Paulo H. Bertolucci, & Dartiu X. Da Silveira Journal of Psychoactive Drugs, 2005, 37, (2), 123-128. Abstract The purpose of the study was to evaluate neuropsychologically adolescents who use ayahuasca in a religious context. A battery of neuropsychological tests was administered to adolescents who use ayahuasca. These subjects were compared to a matched control group of adolescents who did not use ayahuasca. The controls were matched with regards to sex, age, and education. The neuropsychological battery included tests of speeded [...]
Lire la suiteOral Cannabidiol Does Not Convert to Δ8-THC or Δ9-THC in Humans : A Pharmacokinetic Study in Healthy Subjects Jose´ Alexandre S. Crippa, Antonio Waldo Zuardi, Jaime Eduardo Cecılio Hallak, Bruna Miyazawa, Sandra Aparecido Bernardo, Carmem Maria Donaduzzi, Silvane Guzzi, Wagner Alex Jann Favreto, Alline Campos, Maria Eugenia C. Queiroz, Francisco S. Guimaraes, Patrıcia Moura da Rosa Zimmermann, Letıcia Mello Rechia, Volnei Jose Tondo Filho, and Liberato Brum Junior Cannabis and Cannabinoid Research, 2019, Volume X, Number X DOI: 10.1089/can.2019.0024 Abstract Introduction: Recent studies have suggested that cannabidiol (CBD) could interconvert into Delta-8- and Delta-9- tetrahydrocannabinol. Materials and Methods: Thus, we tested the plasma samples of 120 healthy [...]
Lire la suiteComparison of the Neurotoxic and Seizure-Inducing Effects of Synthetic and Endogenous Cannabinoids with Δ9-Tetrahydrocannabinol Chris S. Breivogel, Jacob R. Wells, Amreen Jonas, Artik H. Mistry, Morgan L. Gravley, Rajul M. Patel, Brianna E. Whithorn, and Bonnie M. Brenseke Cannabis and Cannabinoid Research, 2019, Volume X, Number X DOI: 10.1089/can.2019.0003 Abstract Introduction : Synthetic cannabinoids (SCs) are commonly found in preparations used as recreational drugs. Although severe adverse health effects are not generally associated with cannabis use, a rising number of studies document seizures and even death after SC use. In this study, a mouse model is used to investigate the hypothesis that SCs are more [...]
Lire la suiteCannabinoids, Endocannabinoids and Cancer Daniel J. Hermanson and Lawrence J. Marnett Cancer Metastasis Reviews, 2011, 30, (3-4), 599–612. doi:10.1007/s10555-011-9318-8. 1. Introduction 1.1 Cannabinoid Function Endocannabinoids are bioactive lipids that have a range of interesting activities mediated by two G-protein-coupled receptors (CB1 and CB2) and other putative targets [1-3]. The CB1 receptor is present in the central nervous system and mediates the psychotropic effects of exogenous cannabinoids such as Δ9-tetrahydrocannabinol (THC), the active component of marijuana. In the brain, endocannabinoids and cannabinoids combine with CB1 cannabinoid receptors on axon terminals and regulate ion channel activity and neurotransmitter release [4]. Binding to the CB1 receptor is responsible for [...]
Lire la suiteOpportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 Doi : 10.1177/1758835919866362 Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review [...]
Lire la suiteCould Cannabidiol be a Treatment Option for Intractable Childhood and Adolescent Epilepsy ? Chung Mo Koo, Hoon-Chul Kang Journal of Epilepsy Research, 2017, 7, 16-20. pISSN 2233-6249 / eISSN 2233-6257 www.kes.or.kr Epilepsy is an important disease that affects brain function, particularly in those under 3 years old. Uncontrolled seizures can affect cognitive function and quality of life. For these reasons, many trials have been conducted to investigate treatments for pediatric epilepsy. Currently, many antiepileptic drugs are available for the treatment of epilepsy, but cases of intractable epilepsy continue to exist. In the past, cannabis has been tested as a potential treatment of intractable epilepsy. Since [...]
Lire la suiteDon’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy - Commentary M. Scott Perry Epilepsy Currents, 2019, Vol. 19, (2), 93-95 DOI: 10.1177/1535759719835671 Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med, 2018, 378, 1888-1897. Background : Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. Methods : In this double-blind, placebo-controlled trial conducted [...]
Lire la suiteDosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716 Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]
Lire la suiteThe protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]
Lire la suite